Sellas cancer vaccine significantly extends survival in AML trial
Sellas Life Sciences reported its experimental vaccine for acute myeloid leukemia significantly reduced risk of death in a late-stage clinical trial, sending shares to a record single-day surge. The unexpected positive result offers new hope for a difficult-to-treat blood cancer.